Clinical Trial

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

Completed
View on ClinicalTrials.gov →
Summary
Kidney transplant rejection remains a significant challenge to long-term graft survival. While histological biopsy continues to be the gold standard for diagnosing rejection, noninvasive biomarkers such as donor-derived cell-free DNA (dd-cfDNA) have gained traction for their ability to detect allograft injury. However, dd-cfDNA may lack sensitivity in certain clinical scenarios particularly in cases of localized immune activation leading to false negatives despite biopsy-confirmed rejection.
Protocol Amendment History 4 changes
critical Trial completed 2026-07-16
notable Enrollment reduced: 50 -> 20 participants 2026-07-16
notable Primary completion moved earlier: 2027-01 -> 2026-07-01 2026-07-16
minor Completion moved earlier: 2027-01 -> 2026-07-01 2026-07-16
Trial Details
NCT Number NCT07415876
Lead Sponsor Virginia Commonwealth University
Collaborators: Thermo Fisher Scientific, Inc
Conditions Kidney Transplant Rejection
Enrollment 20 participants
Start Date 2026-06-04
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-15